ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2024
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs.Systematic reviews · 2026Pooled it
- Comparative Efficacy of Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, and Neoadjuvant Chemo-Endocrine Therapy in Estrogen Receptor-Positive Breast Cancer Patients: A Meta-Analysis.The breast journal · 2025Pooled it
- Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Trial
- Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study.BMC medicine · 2026Trial
- Perioperative Body-Composition and Phase-Angle Measures in Women Undergoing Breast Cancer Surgery After Neoadjuvant Chemotherapy or Treated Through a Surgery-First Pathway (BC-NUTRITION): Exploratory 2-Cohort Pilot Analysis.JMIR formative research · 2026Observational
- Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review).Oncology letters · 2026Review
- Mesoporous-Shell Monolayer Plasmonic Architecture Enables Quantitative and Decision-Guided SERS.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Invasive Breast Cancer Complicated by Colitis After TCbHP Chemotherapy: A Case Report.The American journal of case reports · 2026Article
- Traditional Chinese Medicine Combined With Chemotherapy for Mammary Paget's Disease With Multifocal Heterogeneous Breast Cancer: A Case Report.Clinical case reports · 2026Article
- Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong.Breast (Edinburgh, Scotland) · 2026Article
- CDK4/6 inhibitor combined with endocrine therapy: a real-world evaluation of efficacy and safety in HR+/HER2- advanced breast cancer.World journal of surgical oncology · 2026Article
- Comparison of neoadjuvant TCbHP versus THP in HER2-positive breast cancer: a retrospective cohort study.Gland surgery · 2026Article
- Locoregional control of downstaged breast-conserving surgery after neoadjuvant chemotherapy: A propensity-matched study in Chinese patients.Breast (Edinburgh, Scotland) · 2026Article
- Noninvasive stratification of HER2 status in breast cancer using multiparametric DECT: a prospective cohort study.International journal of surgery (London, England) · 2026Article
- Efficacy and safety of antibody-drug conjugates for HR+/HER2-low advanced breast cancer: a systematic review with Bayesian network meta-analysis and real-world study.Translational cancer research · 2026Article
- Observational
- Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.Cancer medicine · 2026Article
- Identifying research gaps in PIK3CA-mutant breast cancer: a bibliometric analysis of evolving trends and clinical applications.Translational cancer research · 2026Article
- Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.BMC women's health · 2026Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Committee. Methods: Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO BC experts, the CSCO BC guidelines determine the levels of recommendations for clinical application. Results: For human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a combination of trastuzumab and pertuzumab regimen were recommended as Level I recommendation for neoadjuvant and first line metastatic breast cancer. Pyrotinib is also recommended as Level I recommendation in first line and second line therapy according to the latest studies conducted in China. Antibody drug conjugates was also recommended for patients with trastuzumab progression. For triple negative breast cancer, immunotherapy in early and metastatic breast cancer was highlighted and listed as new chapters in this version of guideline. For hormone receptor (HR)-positive breast cancer, cyclin dependent kinase 4/6 (CDK4/6) was recommended in different stages, especially in adjuvant therapy. There was also a new chapter for HER2-low breast cancer stratified by HR status. Conclusions: We firmly believe that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice in China and in other countries with similar situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.